Key Takeaways
- Domestic rebound, U.S. drag: Revenue grew ~9% YoY, powered by a domestic recovery that outperformed IPM growth, while the U.S. business de-grew against a tough flu-season comparable.
- Margins expanded 160 bps: EBITDA margin reached 21.3%, driven by gross margin gains from lower API costs and easing U.S. price erosion, plus a seasonal drop in other expenses.
- Chronic portfolio turning a corner: The antidiabetic franchise, a prior pain point, grew 16%+ against a market growing 5%, and management expects the chronic mix to shift from ~17% of the portfolio to above 20% over 3-5 years.
- Biosimilars nearing breakeven: The Enzene subsidiary is on track to break even this year, with ~₹200 crores in gross revenue across CDMO and branded products, and a new U.S. facility planned at a cost of ~₹250 crores.
- What to watch next quarter: Whether the 17% full-year margin exit materializes despite Q4’s seasonal weakness, the pace of chronic portfolio mix shift, and any update on the Suprep launch timeline.
Domestic Business: Recovery and Portfolio Shift
- Broad-based rebound: After sluggish H1 growth driven by seasonality, the domestic business saw good offtake in Q3 and outperformed IPM growth by nearly 20 bps, led by gastro, VMN, and antidiabetic portfolios.
- Chronic outperformance: The antidiabetic portfolio, previously a drag, grew at 16%+ against a market growing only 5%, signaling that the chronic turnaround is gaining traction.
- Anti-infective headwind: Anti-infective growth remains sluggish because Alkem is strong in specific geographies where those markets slowed, and the AMOXICLAV market itself has not been progressive this year.
- Pain management lagging: The pain management portfolio’s contribution is not very high and has not been among the most progressive portfolios; management has taken note.
- Chronic ambition: Management expects the chronic portfolio pie to shift from the current ~17% to upwards of 20% over a 3- to 5-year horizon, with chronic growing much faster than the rest of the portfolio and beating market growth.
Vikas Gupta: "So on a 3- to 5-year basis, clearly, I would see the pie changing. So today, we are at close to 17%, but I see upwards of 20% in the coming years as we move -- as we keep growing that business."
Margin Walk and Cost Structure
- Gross margin tailwind: Gross margin improved approximately 2% on account of lower API prices, a benefit management expects to sustain at current levels.
- Other expenses fell sequentially: Other expenses dropped from ₹811 crores in Q2 to ₹740 crores in Q3, driven by seasonality (Q2 carries higher sales and marketing spend), a domestic-vs-international mix shift (international generics carry lower marketing costs), reduced air freight from efficiency projects, and a 0.2% forex element.
- Operating leverage thesis: Management expects sales to grow in the lower- or higher-double-digit range while expenses will not grow at the same pace, so operating leverage will play its part.
- Sales and marketing rationalization: The company is actively working to rationalize sales and marketing expenses, which will help improve EBITDA margin and reduce other expenses over time.
- Cost containment initiatives: Efficiency improvements at plants, development of alternate API vendors, and engagement with large consultants to identify cost reduction opportunities in manufacturing overheads, yield improvement, and better API rates are all underway.
- Red Sea freight impact: Freight costs have increased from the Red Sea disruption, but a significant reduction in air freight has offset it so far; the net impact may sustain unless there is a very large spike in the Red Sea situation.
Vikas Gupta: "At 17%, I believe that should be sustainable. And going forward, we should look at improving it further. But that itself at 16% -- sorry, at 17% itself, we have 50 to 100 basis points improvement."
U.S. Business: Easing Erosion, Margin Recovery
- Revenue de-growth on tough comp: The U.S. business declined YoY because the prior-year quarter benefited from a significant flu outbreak that did not repeat.
- Price erosion bottoming out: U.S. price erosion has moved to single-digit levels, down from the very high double-digit erosion of previous years, and management believes prices are getting bottomed out, though they may not have totally bottomed yet.
- Margin improvement in U.S.: There has been significant improvement in the EBITDA margin of the U.S. business, helped directly by the slowing pace of price erosion.
- U.S. margin profile: The U.S. market carries a slightly lower margin than the corporate average, but management says it is not so low that it is unsustainable.
- St. Louis facility closed: The St. Louis unit has been shut down, removing a cost overhang.
- Suprep launch still distant: The product has not yet been launched and management says it is still a bit away, with no firm timeline to share.
Vikas Gupta: "So see U.S., the price erosion now is a single-digit price erosion, unlike the previous year's price erosion, which used to be a very high double-digit kind of price erosion. So I would say the prices are getting bottomed out."
International ex-U.S. and Biosimilars
- Non-U.S. international as a growth and margin driver: The non-U.S. international business contributed significantly to both revenue and profitability, with growth coming from Latin America and Europe; these markets carry much higher EBITDA margins than the U.S.
- Momentum expected to continue: Management expects the growth momentum in non-U.S. markets to continue through FY25 and FY26 as the organization increases its focus on these geographies.
- Biosimilars nearing breakeven: The Enzene subsidiary will break even this year, grossing approximately ₹200 crores from the biosimilar business including CDMO, with 7 products launched and all performing well.
- U.S. biosimilar facility: A new U.S. facility for Enzene is being built, primarily targeting the biosimilar CDMO business, at a total cost of approximately ₹250 crores, coming up over the next 2 to 3 years; after this, no further major CapEx expansion is needed.
- Learning curve advantage: Management says it is much ahead on the learning curve for setting up U.S. facilities, and the pipeline supporting the new plant is robust and not as competitive.
Capital Allocation and Investment
- Cash deployment search: The company is looking at various opportunities to deploy its strong balance sheet cash, including acquisitions and newer growth opportunities, but no acquisition is currently available at the right valuation.
- R&D spend steady: R&D spend will end the year around 4% of revenue and is expected to remain in the 4% to 4.5% range for the coming years; Q4 R&D is typically higher because more U.S. filings happen in that quarter and filing expense is a major contributor.
- Organic CapEx contained: Organic CapEx will run between ₹300 crores and ₹350 crores; outside of the biosimilar facility, sufficient capacity exists for other businesses with no major increase planned.
- Tax rate trajectory: The tax rate will remain at 10% to 12% for at least the next 2 to 3 years (current year and next year around 11% to 12%), after which it will rise to the 20% to 25% range post FY26.
- MR expansion on hold: No substantial medical representative expansion is planned; future growth will be productivity-led.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year EBITDA margin | Close the year at around 17% | FY24 exit (Q4) |
| Sustainable margin floor | 17% EBITDA margin should be sustainable, with 50-100 bps improvement possible going forward | FY24 and beyond |
| Annual margin improvement | 100 bps improvement each year, guidance remains | Ongoing, annual |
| R&D spend range | 4% to 4.5% of revenue | Coming years |
| Organic CapEx range | ₹300 crores to ₹350 crores | Ongoing |
| Biosimilar breakeven | Enzene subsidiary to break even | This year (FY24) |
| U.S. biosimilar facility | New facility at ~₹250 crores, no further major CapEx thereafter | Next 2 to 3 years |
| Tax rate | 10% to 12% | At least next 2-3 years (through ~FY26) |
| Tax rate post-FY26 | Rise to 20% to 25% range | After FY26 |
| Chronic portfolio mix | Shift from ~17% to above 20% of portfolio | 3 to 5 years |
| Non-U.S. international growth | Growth momentum to continue | FY25 and FY26 |
| U.S. price erosion | Single-digit erosion expected to continue | Ongoing |
| API price levels | Improvement should stay at current levels | Ongoing |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue growth | ~9% YoY |
| EBITDA margin | 21.3%, improved 160 bps YoY from 19.7% |
| Net profit after tax | ₹595 cr |
| Cash generated | ~₹600 cr during the quarter |
| YTD EBITDA margin | 18.9% |
| Full year EBITDA margin guidance | ~17% |
| Domestic business growth vs IPM | +20 bps outperformance |
| Chronic contribution to domestic sales | ~17% |
| Antidiabetic portfolio growth | ~16%+, vs market growth of 5% |
| Other expenses | ₹740 cr, down from ₹811 cr in Q2; 22.3% of sales vs 23.6% in Q2 |
| ANDA approvals | 6, including 1 tentative approval |
| Biosimilar business (Enzene) gross revenue | ~₹200 cr annual run rate |
| R&D spend | 3.4% of sales in Q3, expected to end year at ~4% |
| NLEM portfolio exposure | 28% to 32% of domestic sales |
| Effective tax rate | 11% to 12% for current and next year |